Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
US Department of Justice

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,239,124

« Back to Dashboard

Which drugs does patent 6,239,124 protect, and when does it expire?

Patent 6,239,124 protects ZORTRESS and is included in one NDA. There has been one Paragraph IV challenge on Zortress.

Protection for ZORTRESS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,239,124

Title: Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
Abstract:A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
Inventor(s): Zenke; Gerhard (Rheinfelden, DE), Schuurman; Hendrik (Basel, CH), Haeberlin; Barbara (Riehen, CH), Meinzer; Armin (Buggingen, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:09/230,618
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Dosage form; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
NovartisZORTRESSeverolimusTABLET;ORAL021560-001Apr 20, 2010RXYesNo► Subscribe► Subscribe► SubscribeY
NovartisZORTRESSeverolimusTABLET;ORAL021560-002Apr 20, 2010RXYesNo► Subscribe► Subscribe► SubscribeY
NovartisZORTRESSeverolimusTABLET;ORAL021560-003Apr 20, 2010RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,239,124

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9615942Jul 30, 1996
United Kingdom9705684Mar 19, 1997
PCT Information
PCT FiledJuly 29, 1997PCT Application Number:PCT/EP97/04123
PCT Publication Date:February 05, 1998PCT Publication Number: WO98/04279

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: